scholarly journals The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States

Hepatology ◽  
2013 ◽  
Vol 58 (1) ◽  
pp. 54-64 ◽  
Author(s):  
Phil McEwan ◽  
Thomas Ward ◽  
Yong Yuan ◽  
Ray Kim ◽  
Gilbert L'Italien
Keyword(s):  
United States ◽  
Hepatitis C Virus ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Birth Cohort ◽  
The United States ◽  
The Cost ◽  
The Impact

scholarly journals Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States

2019 ◽  
Vol 69 (11) ◽  
pp. 1888-1895 ◽  
Author(s):  
Antoine Chaillon ◽  
Elizabeth B Rand ◽  
Nancy Reau ◽  
Natasha K Martin
Keyword(s):  
United States ◽  
Hepatitis C Virus ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Pregnant Women ◽  
Cost Effective ◽  
The United States ◽  
Lifetime Horizon ◽  
Hcv Screening ◽  
The Cost

Abstract Background Hepatitis C virus’ (HCV) chronic prevalence among pregnant women in the United States doubled nationally from 2009–2014 (~0.7%), yet many cases remain undiagnosed. Screening pregnant women is not recommended by the Society of Maternal-Fetal Medicine or the Centers for Disease Control and Prevention, despite new American Association For the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidelines recommending screening for this group. We assessed the cost-effectiveness of HCV screening for pregnant women in the United States. Methods An HCV natural history Markov model was used to evaluate the cost-effectiveness of universal HCV screening of pregnant women, followed by treatment after pregnancy, compared to background risk-based screening from a health-care payer perspective. We assumed a HCV chronic prevalence of 0.73% among pregnant women, based on national data. We assumed no Medicaid reimbursement restrictions by fibrosis stage at baseline, but explored differing restrictions in sensitivity analyses. We assessed costs (in US dollars) and health outcomes (in quality-adjusted life-years [QALYs]) over a lifetime horizon, using new HCV drug costs of $25 000/treatment. We assessed mean incremental cost-effectiveness ratios (ICERs) under a willingness-to-pay threshold of $50 000/QALY gained. We additionally evaluated the potential population impact. Results Universal antenatal screening was cost-effective in all treatment eligibility scenarios (mean ICER <$3000/QALY gained). Screening remained cost-effective at a prevalence of 0.07%, which is the lowest estimated prevalence in the United States (in Hawaii). Screening the ~5.04 million pregnant women in 2018 could result in the detection and treatment of 33 000 women, based on current fibrosis restrictions. Conclusions Universal screening for HCV among pregnant women in the United States is cost-effective and should be recommended nationally.

scholarly journals Setting-based Prioritization for Birth Cohort Hepatitis C Virus Testing in the United States

2019 ◽  
Vol 70 (3) ◽  
pp. 543-544
Author(s):  
Brooke R MacDonald ◽  
Tzu-Chun Chu ◽  
Rachel A Stewart ◽  
Rohit P Ojha
Keyword(s):  
United States ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Birth Cohort ◽  
The United States ◽  
Virus Testing

scholarly journals Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States

2015 ◽  
Vol 162 (6) ◽  
pp. 397 ◽  
Author(s):  
Jagpreet Chhatwal ◽  
Fasiha Kanwal ◽  
Mark S. Roberts ◽  
Michael A. Dunn
Keyword(s):  
United States ◽  
Hepatitis C Virus ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Budget Impact ◽  
The United States
Sign in / Sign up

Export Citation Format

Share Document